Arrow
Arrow
Liv Hekimleri
Arrow
Doç. Dr. Emir Çelik
Doç. Dr. Emir Çelik
Doç. Dr.

Emir Çelik

İstinye Üniversitesi Liv Hospital Topkapı
Tıbbi Onkoloji
İlgi Alanları
    • Kişiselleştirilmiş Tedaviler
    • NGS ve Moleküler Onkoloji
    • Prostat kanseri
    • Böbrek ve Mesane kanseri
    • Meme kanseri
    • Akciğer Kanseri
    • Mide ve Kolorektal kanserler
    • Jinekolojik kanserler
    • Malign Melanom ve Sarkomlar
Özgeçmişim
Yayınlarım
Üyeliklerim
Eğitim:
  • Alanya Fen Lisesi 2007
  • Cerrahpaşa Tıp Fakültesi 2007-2013
  • Cerrahpaşa Tıp Fakültesi, İç Hastalıkları 2014-2018
  • Cerrahpaşa Tıp Fakültesi, Tıbbi Onkoloji 2018-2021
Deneyim:
  • Muş Devlet Hastanesi 2021-2023 (Mecburi Hizmet)
  • Haydarpaşa Numune Eğitim ve Araştırma Hastanesi 2023
  • İstanbul Prof. Dr. Cemil Taşçıoğlu Şehir Hastanesi 2023-2025
Uluslararası Dergilerde Yayınlanan Makalelerim:
  • Aydin O, Erciyestepe M, Öztürk AE, Dinç G, Uysal E, Atci MM, Ertürk K, Celik E. Comparison of clinical and prognostic characteristics of patients with classic and AIDS-related Kaposi sarcoma: A single-center experience. Medicine (Baltimore). 2025 Aug 1;104(31):e43576.
  • Atçı M, Celik E, Cicin I. Advancing prognostic precision in unplanned oncology admissions: the promise of the PROMISE-CTI score. Lancet Reg Health Eur. 2025 Jun 6;54:101336.
  • Fidan MC, Öztürk AE, Aydın O, Akdağ G, Türkoğlu E, Çolak R, Majidova N, Kapağan T, Guliyev M, Celik E, Odabaş H, Yılmaz M, Bayoğlu İV, Bulut N, Demirci NS, Alan Ö. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data. J Clin Med. 2025 Jun 27;14(13):4568.
  • Aydın O, Öztürk AE, Erciyestepe M, Sonuşen ŞD, İşleyen ZS, Dinçer ST, Celik E, Ertürk K, Atcı MM. The Effect of Total Neoadjuvant Treatment on Pathological Response and Survival in Locally Advanced Rectal Cancer: A Single Center Experience. Clin Colorectal Cancer. 2025 Sep;24(3):369-377.e1.
  • Erciyestepe M, Ekinci ÖB, Doğan HGY, Öztürk AE, Aydın O, Büyükkuşcu A, Atasever T, Uslu BS, Akkaya K, Celik E, Ertürk K, Atcı MM. Factors affecting survival and prognosis in extensive stage small cell lung cancer. BMC Pulm Med. 2025 Apr 8;25(1):160.
  • Babacan GB, Öner Tamam M, Saraçoğlu S, Acar Tayyar MN, Şahin MC, Özçevik H, Kulduk G, Ekinci ÖB, Celik E. Novel heterogeneity method for predicting survival in non-metastatic triple-negative breast cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2025 Sep-Oct;44(5):500112.
  • Erciyestepe M, Aydin O, Dinc Sonusen S, Ozturk AE, Celik E, Atci MM, Erturk K. Distribution of side effects of anti-EGFR treatments in patients with metastatic colorectal cancer and evaluation of their relationship with survival. Anticancer Drugs. 2025 Jul 7.
  • Erciyestepe M, Ekinci ÖB, Seçmeler Ş, Selvi O, Öztürk AE, Aydin O, Büyükkuşcu A, Atasever T, Celik E, Ertürk K, Atci MM. Evaluation of ixabepilone efficacy and tolerability in metastatic breast cancer. Medicine (Baltimore). 2024 Nov 22;103(47):e40649.
  • Sengul N, Gültürk I, Yilmaz M, Celik E, Paksoy N, Yekedüz E, Ürün Y, Basaran M, Özgüroğlu M. Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function. Actas Urol Esp (Engl Ed). 2024 Apr 1:S2173-5786(24)00029-5. English, Spanish.
  • Erciyestepe M, Selvi O, Dinç G, Öztürk AE, Aydın O, Dinç Sonuşen Ş, Güneş TK, Avcı T, Vatansever S, Celik E, Atcı MM. Factors affecting recurrence and survival in Stage IIA colon cancer patients. Oncology. 2024 Jul 15.
  • Demirci NS, Çavdar E, Erdem GU, Hatipoglu E, Celik E, Sezer S, Yolcu A, Dogan M, Seber ES. Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer? Medicine (Baltimore). 2023 Jun 23;102(25):e34014.
  • Iriagac Y, Cavdar E, Karaboyun K, Tacar SY, Akkoc Mustafayev FN, Celik E, Avci O, Okutur SK, Koral L, Demirci NS, Ozgun A, Seber ES. Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib. J Cancer Res Ther. 2023 Jan-Mar;19(2):376-381.
  • Erol C, Sendur Mehmet AN, Bilgetekin I, Garbioglu DB, Hamdard J, Akbas S, Hizal M, Arslan C, Sevinc A, Kucukarda A, Erdem D, Kahraman S, Cakir E, Demirkiran A, On S, Dogan I, Erdogan AP, Koca S, Kubilay P, Eren OO, Cilbir E, Celik E, Araz M, Ozyukseler DT, Yildirim ME, Bahceci A, Taskaynatan H, Oyman A, Deniz GI, Menekse S, Kut E, Gulmez A, Sakin A, Nayir E, Acar R, Sen E, Inal A, Turhal S, Kaya AO, Paydas S, Tastekin D, Hacibekiroglu I, Cincin I, Bilici A, Mandel NM, Dede DS, Akinci MB, Oksuzoglu B, Uncu D, Yalcin B, Artac M. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. J Cancer Res Ther. 2022 Dec;18
  • Samanci NS, Guliyev M, Degerli E, Celik E, Turna ZH. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report. J Cancer Res Ther. 2022 Apr-Jun;18(3):792-794.
  • Celik E, Ozturk T, Samanci NS, Demirci NS, Akovali B, Demirelli FH. Breast cancer to thyroid gland: An unconventional metastatic site. J Cancer Res Ther. 2022 Apr-Jun;18(3):788-791.
  • Gursoy P, Tatli AM, Erdem D, Goker E, Celik E, Demirci NS, Sakin A, Atci MM, Bayram E, Telli TA, Bilgin B, Bilici A, Akangunduz B, Balli S, Demirkazik A, Selçukbiricik F, Menekse S, Cavdar E, Ozturk A, Bekmez ET, Turhal S, Kilickap S, Yildirim HÇ, Oyan B, Aksoy A, Turkoz FP, Kut E, Katgi N, Sakalar T, Akyol M, Ellez Hİ, Topcu A, Erdoğan AP, Pilanci KN, Hedem E, Arak H, Akdeniz N, Alan Ö, Yapar B, Nart D, Yumuk PF. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2023 Feb;149(2):865-875.
  • Celik E, Samanci NS, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Alkan G, Senyigit A, Turna ZH. A single center's experience of the extrapulmonary neuroendocrine carcinomas. North Clin Istanb. 2021 Feb 14;9(1):35-40.
  • Celik E, Suzan V, Samanci NS, Suzan AA, Karadag M, Sahin S, Aslan MS, Yavuzer H, Demirci NS, Doventas A, Demirelli FH. Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors. Eur Geriatr Med. 2022 Feb;13(1):267-274.
  • Celik E, Aslan MS, Sengul Samanci N, Karadag M, Saglam T, Cakan Celik Y, Demirci NS, Demirelli FH. The Relationship Between Symptom Severity and Caregiver Burden in Cancer Patients Under Palliative Care: A Cross-Sectional Study. J Palliat Care. 2022 Jan;37(1):48-54.
  • Değerli E, Derin S, Oruç K, Şengül Samancı N, Bedir Ş, Celik E, Şentürk Öztaş N, Alkan G, Demirelli FH, Demirci NS. The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID-19 patients with malignancy: A single-center experience. J Med Virol. 2021 Oct;93(10):5839-5845.
  • Sengul Samanci N, Celik E, Bagcilar O, Tutar O, Samanci C, Velidedeoglu M, Yassa AE, Demirci NS, Demirelli FH. Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection. J Surg Oncol. 2021 May;123(8):1757-1763.
  • Celik E, Samanci NS, Karadag M, Demirci NS, Demirelli FH, Ozguroglu M. The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer. Med Oncol. 2021 Jan 16;38(1):11.
  • Bilgin B, Sendur MAN, Yucel S, Celik E, Ozyukseler DT, Ayhan M, Basoglu T, Ilhan A, Akdeniz N, Gulmez A, Dogan I, Aktas BY, Gurbuz M, Koca S, Paydas S, Tatli AM, Cinkir HY, Alan O, Erol C, Hizal M, Kut E, Menevse S, Sakalar T, Taskaynatan H, Deniz GI, Karaagac M, Avci O, Sen E, Karatas F, Akinci MB, Dede DS, Demir A, Demirkazık A, Oksuzoglu B, Kilickap S, Yumuk F, Yalcin B. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152.
  • Celik E, Samanci NS, Karadag M, Demirci NS, Cikman DI, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Demirelli FH. Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. J Oncol Pharm Pract. 2021 Oct;27(7):1665-1673.
  • Celik E, Dokur, M., Börkü Uysal, B., Şengül Samancı, N., & Demirelli, F. H. (2020). Comparison of attention for cancer research on social media versus academia: An altmetric score analysis.
  • Ozkaya HM, Sahin S, Korkmaz OP, Durcan E, Sahin HR, Celik E, Poyraz BC, Kadioglu P. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. Growth Horm IGF Res. 2020 Dec;55:101356.
  • Sengul Samanci N, Cikman DI, Oruc K, Bedir S, Celik E, Degerli E, Derin S, Demirelli FH, Özgüroğlu M. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer. Tumori. 2021 Aug;107(4):304-310.
  • Sengul Samanci N, Celik E, Bagcilar O, Erol BC, Bicki E, Oruc K, Bedir S, Degerli E, Derin S, Demirci NS, Demirelli FH. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. Melanoma Res. 2020 Oct;30(5):477-483.
  • Samanci NS, Akdogan S, Celik E, Kutlu O, Ulgen OA, Demirelli FH. Facial cutaneous metastasis of rectal adenocarcinoma. North Clin Istanb. 2020 Jul 23;8(5):518-520.
  • Celik E, Dokur M. The most cited articles on cancer immunotherapy: An update study. J BUON. 2020 Mar-Apr;25(2):1178-1192.
  • Samanci NS, Celik E. The top 100 cited articles in lung cancer - a bibliometric analysis. Contemp Oncol (Pozn). 2020;24(1):17-28. doi: 10.5114/wo.2020.94725. Epub 2020 Mar 30.
  • Sengul Samanci N, Yılmaz U, Bedir S, Ozgur Yurttas N, Oruc K, Durak Sahin Z, Celik E, Toplutas KN, Akı H, Eskazan AE, Demirelli FH. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation. J Oncol Pharm Pract. 2020 Dec;26(8):2042-2046.
  • Sengul Samanci N, Ozan T, Celik E, Demirelli FH. Optic Neuritis Related to Atezolizumab Treatment in a Patient With Metastatic Non-Small-Cell Lung Cancer. JCO Oncol Pract. 2020 Feb;16(2):96-98.
  • Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine. 2018 Dec;62(3):692-700.
Ulusal Dergilerde Yayınlanan Makalelerim:
  • Samanci, N. S., Gursu, R. U., Bozkaya, Y., Arslan, E., Ulusan, M. B., Trablus, F. D. C., Havare S.B., Karadeniz C., Celik E, Mermut, O. (2021). Response Rates and Predictive Factors of Pathological Complete Response to Neoadjuvant Chemotherapy in Luminal B HER2 Negative Breast Cancer. Eurasian J Med Investig, 5, 476-80.
  • Celik E, Aslan, M. S., Samancı, N. S., Karadağ, M., Suzan, V., Çakan Çelik, Y. Demirci, N. S., Demirelli, F. H., (2021). Risk of Malnutrition and Its Effects on the Quality of Life of Hospitalized Cancer Patients. Namık Kemal Tıp Dergisi.
  • Samanci, N. S., Celik E, Taparli, O. E., Degerli, E., Demirci, N. S., Demirelli, F. H., (2021). Effect of Smoking Status on Hematological Toxicities and Effectiveness of First-line Platinum-based Chemotherapy Administered to Patients with Non-small-cell Lung Cancer. Eurasian Journal of Medical Investigation, 5(2), 189-195.
  • Celik E, Samanci, N. S., Karadag, M., Demirci, N. S., Demirelli, F. H. (2021). Could Systemic Inflammation-Based Prognostic Scores Predict the Clinical Outcome in Patients with Breast Cancer Treated with Everolimus Plus Exemestane?. Eurasian Journal of Medical Investigation, 5(2), 225-231.
  • Suzan, V., Yavuzer, H., Bayramlar, O. F., Emiroglu, T., Arman, P., Bag, R., Unal D., Surme S., Celik E, Doventas A., Erdincler, D. S. Effect of Pneumococcal Vaccination and Other Factors on Prognosis in Patients Following with Pneumonia in Geriatric Clinic.
  • Samanci, N. Ş., Celik E, Degerli, E., Kasap, M., Kerem, O., Bedir, S., Derin S., Senturk N., Poyraz B., Turna Z., Demirelli, F. Factors of affecting sleep quality in cancer patients. Namık Kemal Tıp Dergisi, 8(2), 138-144.
C. Yazar Olduğum Kitap Bölümleri:
  • Celik E: Preserving Bone Health in All Stages of Breast Cancer, Edited by Ahmet Ertaş, Atakan Demir, Ayşe Altınok, Cihan Uras, Gül Esen İçten. Ankara Nobel Press, 2021.
  • Celik E: Cancer Chemotherapy, Edited By Zeliha Yazıcı, Burak Önal. Ankara Nobel Press, 2021
  • Celik E: Primary Thyroid Lymphoma, Edited by Atakan Demir. Istanbul Logos Press, 2019
  • European Society for Medical Oncology (ESMO)
  • Türk Tıbbi Onkoloji Derneği
  • American Society of Clinical Oncology (ASCO)
  • Sigma Xi Full Member
  • Erken Faz Klinik Araştırmalar ve Yenilikçi İlaçlar Derneği (EFKAD) 
Hekime Sor
Formu Eksiksiz Doldurunuz.